UY37848A - Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 - Google Patents

Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3

Info

Publication number
UY37848A
UY37848A UY0001037848A UY37848A UY37848A UY 37848 A UY37848 A UY 37848A UY 0001037848 A UY0001037848 A UY 0001037848A UY 37848 A UY37848 A UY 37848A UY 37848 A UY37848 A UY 37848A
Authority
UY
Uruguay
Prior art keywords
nlrp3
compounds
sulfonilureas
sulfoniltioureas
inhibitors
Prior art date
Application number
UY0001037848A
Other languages
English (en)
Inventor
Matthew Cooper
David Miller
Angus Macleod
Stephen Thom
St-Gallay Stephen
Jonathan Shannon
Thomas Alanine
Stuart Onions
Ian Strutt
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713082.4A external-priority patent/GB201713082D0/en
Priority claimed from GBGB1718563.8A external-priority patent/GB201718563D0/en
Priority claimed from GBGB1721726.6A external-priority patent/GB201721726D0/en
Priority claimed from GBGB1721732.4A external-priority patent/GB201721732D0/en
Priority claimed from GBGB1810983.5A external-priority patent/GB201810983D0/en
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of UY37848A publication Critical patent/UY37848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sulfonilureas y sulfoniltioureas que comprenden un anillo de heteroarilo de 5 miembros unido al grupo sulfonilo, donde el anillo de heteroarilo está disustituido en las posiciones 3 y 4 en relación con el punto de unión del grupo sulfonilo, donde al menos uno de los disustituyentes contiene un átomo de nitrógeno. La presente invención se refiere además a sales, solvatos y profármacos de estos compuestos, a composiciones farmacéuticas que comprenden estos compuestos, y al uso de estos compuestos en el tratamiento y la prevención de enfermedades y trastornos médicos, más particularmente mediante la inhibición de NLRP3.
UY0001037848A 2017-08-15 2018-08-15 Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 UY37848A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1713082.4A GB201713082D0 (en) 2017-08-15 2017-08-15 Novel compounds
GBGB1718563.8A GB201718563D0 (en) 2017-11-09 2017-11-09 Novel compounds
GBGB1721726.6A GB201721726D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1721732.4A GB201721732D0 (en) 2017-12-22 2017-12-22 Novel Compounds
GBGB1810983.5A GB201810983D0 (en) 2018-07-04 2018-07-04 Novel compounds

Publications (1)

Publication Number Publication Date
UY37848A true UY37848A (es) 2019-03-29

Family

ID=63371669

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037848A UY37848A (es) 2017-08-15 2018-08-15 Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3

Country Status (5)

Country Link
US (1) US11542255B2 (es)
EP (1) EP3668842A1 (es)
TW (1) TW201910317A (es)
UY (1) UY37848A (es)
WO (1) WO2019034692A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014487A1 (en) 2016-02-16 2017-08-24 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
AU2018210525B2 (en) 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
BR112019024831A2 (pt) 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11773058B2 (en) 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
EP3668862A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
PE20210050A1 (es) * 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (en) * 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
PE20211810A1 (es) 2018-05-04 2021-09-14 Inflazome Ltd Compuestos novedosos
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
CN112437683A (zh) 2018-07-20 2021-03-02 豪夫迈·罗氏有限公司 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物
BR112021002770A2 (pt) 2018-08-15 2021-05-04 Inflazome Limited compostos inovadores de sulfonamidaurea
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
US20220259170A1 (en) * 2019-07-17 2022-08-18 Zomagen Biosciences Ltd Nlrp3 modulators
CN114401971A (zh) 2019-08-16 2022-04-26 英夫拉索姆有限公司 用作nlrp3抑制剂的大环磺酰脲衍生物
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
EP4107153A1 (en) 2020-02-18 2022-12-28 Inflazome Limited Compounds
EP4121059A4 (en) 2020-03-16 2023-12-13 Zomagen Biosciences Ltd NLRP3 MODULATORS
WO2021255279A1 (en) 2020-06-19 2021-12-23 Ac Immune Sa D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
CN114516878B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
IL311784A (en) * 2021-09-29 2024-05-01 Viva Star Biosciences Suzhou Co Ltd Converted sulfonylureas as inhibitors of inlerleukin-1 activity
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
NL129208C (es) 1965-07-14
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
DE3479213D1 (en) 1983-05-16 1989-09-07 Ciba Geigy Ag Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180A (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift.
JPH0720958B2 (ja) 1985-01-18 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホンアミド誘導体、製法および除草剤
CA1231336A (en) 1985-05-30 1988-01-12 George Levitt Herbicidal sulfonamides
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
ES2037738T3 (es) 1986-09-26 1993-07-01 Ciba-Geigy Ag Procedimiento para la obtencion de aminopirazinonas y aminotriazinonas.
US4802908A (en) 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
AU7165591A (en) 1990-01-22 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
ZA915371B (en) 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
WO1992004319A1 (en) 1990-08-29 1992-03-19 E.I. Du Pont De Nemours And Company Herbicidal pyrrolesulfonylureas
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
CZ36294A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
WO1993004046A1 (en) 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH06199054A (ja) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd 熱転写シート
JPH06199053A (ja) 1992-12-28 1994-07-19 Sankyo Kagaku Kk 感熱転写記録用色素
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
AU7007696A (en) 1995-09-22 1997-04-09 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
US5814631A (en) 1995-09-28 1998-09-29 Suntory Limited Quinazoline derivatives and applications thereof
CA2247286A1 (en) 1996-02-26 1997-08-28 Hirohiko Hasegawa Sulfonylureidopyrazole derivatives
EP1270565B1 (en) 1997-01-29 2004-06-30 Pfizer Inc. 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives
DK0964849T3 (da) 1997-01-29 2003-08-25 Pfizer Sulfonyl-urinstofderivater og deres anvendelse ved regulering af interleukin-1-aktivitet
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
EP0987552A3 (en) 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100688740B1 (ko) 1999-03-15 2007-02-28 액시스 파마슈티컬스 인코포레이티드 프로테아제 억제제로서의 ｎ-시아노메틸 아미드
CA2383026A1 (en) 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and compounds that inhibit il-1 processing and release
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
MXPA03010341A (es) 2001-05-18 2004-03-10 Solvay Pharm Gmbh Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.
FI110677B (fi) 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
WO2003045400A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
BR0311419A (pt) 2002-05-28 2005-04-05 Dimensional Pharm Inc Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
ES2334795T3 (es) 2003-10-03 2010-03-16 Portola Pharmaceuticals, Inc. Sulfonilureas 2,4-dioxo-3-quinazolinilarilo.
JP4879745B2 (ja) 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
WO2006039212A2 (en) 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
AR052900A1 (es) 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
WO2009065096A1 (en) 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
JP5688404B2 (ja) 2010-03-05 2015-03-25 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
EP2781216A4 (en) 2011-09-02 2015-05-27 Kyowa Hakko Kirin Co Ltd CHEMOKINREZEPTORAKTIVITÄTSREGLER
PL221813B1 (pl) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
TWI662027B (zh) 2013-11-05 2019-06-11 諾華公司 用於調節泫尼酯（ｆａｒｎｅｓｏｉｄ）ｘ受體之組合物及方法
CN104513239B (zh) 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CA2975192A1 (en) 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2016138473A1 (en) 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
CA3014487A1 (en) 2016-02-16 2017-08-24 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
EP3872070A1 (en) 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3445749B1 (en) 2016-04-18 2022-12-21 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
AU2018210525B2 (en) * 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
BR112019024831A2 (pt) * 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
US11370776B2 (en) * 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
MA56075A (fr) 2017-07-07 2022-04-06 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
MX2020000911A (es) 2017-07-24 2020-09-10 Novartis Ag Star Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
KR20200041918A (ko) 2017-08-15 2020-04-22 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11773058B2 (en) 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN110151749B (zh) 2018-02-13 2022-04-19 中国科学技术大学 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759089A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US20200407340A1 (en) 2018-03-02 2020-12-31 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
PE20211810A1 (es) 2018-05-04 2021-09-14 Inflazome Ltd Compuestos novedosos
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
KR20210030947A (ko) 2018-07-03 2021-03-18 노파르티스 아게 Nlrp3 길항제를 사용한 tnf 억제제 저항성 대상체를 위한 치료 방법 또는 치료제의 선택 방법
CN112437683A (zh) 2018-07-20 2021-03-02 豪夫迈·罗氏有限公司 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
BR112021002770A2 (pt) 2018-08-15 2021-05-04 Inflazome Limited compostos inovadores de sulfonamidaurea
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
BR112021008969A2 (pt) 2018-11-13 2021-08-03 Novartis Ag compostos e composições para tratar condições as-sociadas à atividade de nlrp
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN109432078B (zh) 2018-12-04 2020-09-01 南华大学 一种化合物在制备预防或治疗电离辐射所致认知障碍药物中的应用
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
CN114401971A (zh) * 2019-08-16 2022-04-26 英夫拉索姆有限公司 用作nlrp3抑制剂的大环磺酰脲衍生物
TW202115095A (zh) 2019-08-16 2021-04-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
EP4107153A1 (en) 2020-02-18 2022-12-28 Inflazome Limited Compounds

Also Published As

Publication number Publication date
WO2019034692A1 (en) 2019-02-21
TW201910317A (zh) 2019-03-16
US20210130329A1 (en) 2021-05-06
US11542255B2 (en) 2023-01-03
EP3668842A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
UY37848A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2020004423A (es) Nuevos compuestos de sulfonamida carboxamida.
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2020002851A1 (es) Compuestos novedosos
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2022008091A2 (es) Inhibidores de kras g12c
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2019001495A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
CL2021002144A1 (es) Compuesto heterociclo pentacíclico.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110